Skip to content
Biodatica
Start free

Rigel Pharmaceuticals

Aurora, Colorado

OncologyPhase IIListed · RIGL

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

3w agoTrial registeredJun 29, 2026Source filing (opens the source filing in a new tab)

Momentum

97no change

Momentum 97 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    EARLY_PHASE1 registered

    Aug 3, 2025

    High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma, Glioblastoma, Glioblastoma Multiforme, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Midline Glioma, H3K27-altered · RECRUITING · sponsor: Nationwide Children's Hospital · Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

    ClinicalTrials.gov · NCT06333899 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Feb 1, 2025

    High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma · RECRUITING · sponsor: Rigel Pharmaceuticals · Study of Olutasidenib and Temozolomide in HGG

    ClinicalTrials.gov · NCT06161974 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Dec 16, 2022

    Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma · RECRUITING · sponsor: Nationwide Children's Hospital · ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

    ClinicalTrials.gov · NCT05233397 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Aug 1, 2018

    High Grade Glioma, Diffuse Intrinsic Pontine Glioma · ACTIVE_NOT_RECRUITING · sponsor: Nationwide Children's Hospital · A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma

    ClinicalTrials.gov · NCT03605550 (opens the source filing in a new tab)

  5. Trial

    PHASE2 registered

    Nov 13, 2017

    Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Low Grade Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Hodgkin Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Hodgkin Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Soft Tissue Sarcoma, Rhabdoid Tumor, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Wilms Tumor · COMPLETED · sponsor: National Cancer Institute (NCI) · Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

    ClinicalTrials.gov · NCT03213665 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources